BRIEF-Bristol Myers Says Breast Cancer Drug IZA-BREN Reduces Risk Of Progression Or Death By 59% In Phase 3 Study

5

Oct 23 (Reuters) – Bristol-Myers Squibb Company: * IZALONTAMAB BRENGITECAN (IZA-BREN) REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 59% VERSUS CHEMOTHERAPY IN PATIENTS WITH ADVANCED HR+/HER2- BREAST

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)